March 17, 2020
U.S. researchers on Monday reportedly administered the first shot to the first participant in a clinical trial for an experimental vaccine to protect against the deadly novel coronavirus as cases of the disease continue to surge across the globe.
“Going from not even knowing that this virus was out there … to have any vaccine” in testing in about two months is unprecedented, Dr. Lisa Jackson, the leader of the Kaiser Permanente coronavirus vaccine study, told the Associated Press (AP).
“We don’t know whether this vaccine will induce an immune response, or whether it will be safe. That’s why we’re doing a trial,” Jackson stressed. “It’s not at the stage where it would be possible or prudent to give it to the general population.”
On Monday, U.S. President Donald Trump acknowledged that the “first phase” of the trials had begun.
“This is one of the fastest vaccine development launches in history, not even close,” Trump said.
The first vaccine trial marked only the beginning of the process to determine whether the shots are safe and ready for widespread use, which could take up to a year and a half.
This article was posted: Tuesday, March 17, 2020 at 5:43 am